AS1810722

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

AS1810722 是一种口服有效的 STAT6 抑制剂 (IC50 :1.9 nM)。 AS1810722 显示出良好的 CYP3A4 抑制特性。 AS1810722是稠合双环嘧啶的衍生物，具有用于哮喘等过敏性疾病和特应性疾病研究的潜力。

AS1810722 is an orally active and potent STAT6 inhibitor(IC50 :1.9 nM). AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research.

——

Animal Model:Female Balb/c mice asthmatic model by intraperitoneal injection of ovalbumin (OVA)-containing aluminum hydroxide gel Dosage:0.03-0.3 mg/kg Administration:Orally; 30 min before, and 24 and 48 h after OVA exposure Result:Suppressed eosinophil infiltration in the lung in a dose-dependent manner.

——

Metabolic Enzyme/Protease

P450

CYP3A4|STAT6

——

——

909561-15-5

477.52

C25H25F2N7O

>98% (HPLC)

DMSO : 62.5 mg/mL (130.89 mM; Need ultrasonic)

O=C(N)CN1CCN(C2=CC=C(NC3=NC=C4C(N(CC5=CC(F)=CC(F)=C5)C=C4)=N3)C=C2)CC1

——

(-20℃)

With Ice Pack

≥ 2 years